Barclays 28th Annual Global Healthcare Conference March 12, 2026 9:00 AM EDTCompany ParticipantsTroy Wilson - Chairman, CEO ...

Ocular Therapeutix (NASDAQ:OCUL) reported positive top-line results from its SOL-1 Phase 3 clinical trial evaluating AXPAXLI (also referred to as OTX-TKI) in wet age-related macular degeneration (wet ...

We are continuing to see an increase in the incidence of kidney cancer in younger patients over time. Maintaining kidney health involves basic lifestyle choices: avoiding obesity, not smoking, and ...

Ocular Therapeutix Inc. OCUL shares are down during Tuesday's premarket session following a significant announcement regarding their Axpaxli treatment for wet age-related macular degeneration (AMD).

Although the primary endpoint was not met, axitinib was associated with significantly increased PFS and ORR for patients with previously-treated, advanced extrapancreatic neuroendocrine tumors.

There are many interesting companies that make Bedford their home. Below is a quick recap of what’s happening around town in ...

An Ocular Therapeutix drug developed for the wet form of age-related macular degeneration was better at helping patients maintain vision compared to a blockbuster Regeneron Pharmaceuticals drug that ...

UNESCO and the Advisory Bodies to the World Heritage Committee have issued new guidance for assessing impacts from projects that could potentially affect the planet’s most precious heritage places.

HUTCHMED divested a 45.0% equity interest in SHPL for $608.5 million in cash in April 2025, retaining a 5.0% equity interest. As a result, HUTCHMED’s share of equity in earnings of SHPL in 2025 ...

JIN-A02 is an oral, high-selectivity EGFR inhibitor designed to inhibit C797S and T790M resistance mutations while sparing wild-type EGFR to improve therapeutic index. Preclinical NSCLC models ...

In the NBA today, few players have ever divided fans' opinions more than Cam Thomas. The new Milwaukee Bucks guard has always wowed fans with his potent scoring ability, but teams haven't valued him ...